Financial Statement Analysis Of Solora Active Pharma Science Pvt Ltd

Abstract

The Financial Statement Analysis Of Solora Active Pharma Science Pvt. Ltd., Focusing On Evaluating Its Financial Health, Efficiency, And Sustainability. The Study Aims To Assess The Company’s Liquidity, Solvency, Profitability, And Operational Efficiency Using Comparative And Common-size Statements. Data From 2020–2025 Were Analyzed To Identify Financial Trends. Assets Grew Steadily Until 2022 But Declined From 2023–2025 Due To Reduced Investments In Property, Plant, And Equipment. Equity Peaked In 2021 But Weakened Later, Reducing Financial Stability. Current Liabilities Increased, And Reliance On Short-term Debt Rose, Causing Liquidity Risks. The Current Ratio Dropped Sharply After 2024, Showing Poor Short-term Financial Strength. Leverage Ratios Stayed Stable, But Proprietary Ratios Indicated Uneven Equity Contribution. Overall, Findings Reveal Weakening Financial Strength And Liquidity In Recent Years. The Study Concludes That The Firm Must Improve Liquidity Management, Build Reserves, Retain Profits, And Reduce Dependence On Short-term Borrowings To Ensure Long-term Stability.

Keywords